|Mr. Lewis G. Gradon||MD, CEO & Exec. Director||1.7M||N/A||1961|
|Ms. Andrea Blackie||Acting Chief Financial Officer||N/A||N/A||N/A|
|Dr. Andrew Somervell||VP of Products & Technology||N/A||N/A||N/A|
|Rachel Reynolds||Sr. Communications Mang.||N/A||N/A||N/A|
|Mr. Paul N. Shearer||Sr. VP of Sales & Marketing||N/A||N/A||N/A|
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, and markets medical device products and systems worldwide. The company offers its products for use in respiratory, acute care, and surgery; and for the treatment of obstructive sleep apnea (OSA). It operates through four segments: New Zealand, North America, Europe, and Asia-Pacific. The company offers adult respiratory products, such as AIRVO 2 system, a humidifier with integrated flow source; Optiflow, a nasal high flow therapy; and noninvasive and invasive ventilation systems. It also provides infant respiratory products, including resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. In addition, the company offers surgical humidification systems; and homecare products comprising masks, CPAP devices, data management, humidifiers, and accessories. It markets and sells its products through its distribution subsidiaries, third party distributors, and original equipment manufacturers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Fisher & Paykel Healthcare Corporation Limited’s ISS governance QualityScore as of 1 February 2019 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 6; Compensation: 10.